Detail

Study ID: Abbott XIENCE 90 Study

Title:

Abbott XIENCE 90 Study

Description:
Title: XIENCE 90 Study. Description: The XIENCE 90 Study is designed to evaluate the safety of taking two types of commercially available blood thinning drugs (also known as antiplatelet drugs) for 3 months after the implantation of any commercially available XIENCE stents for patients at high risk of bleeding. The study will gather safety information on the dual use of a P2Y12 inhibitor (antiplatelet drug) for a short period of time (3 months) along with the indefinite use (no time limit) of aspirin (antiplatelet drug) for patients receiving XIENCE stents. To understand the long-term success of 3 months of dual antiplatelet therapy in reducing the incidents of adverse events, study participants will need to return for a few visits during the first 12 months of the study. All data collected during this study will be used to support the use of dual antiplatelet therapy for 3-months following a cardiac stent procedure.
Location:
Sioux Falls Region
Principal Investigator:
Tomasz Stys, MD
Disease:
Heart
Stage:
IDE
Status:
Active - Open to Accrual